Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

BACKGROUND: Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the patients do not respond to these treatments and severe side effects are observed in up to 60%. Therefore, there is a high need...

Descripción completa

Detalles Bibliográficos
Autores principales: Forschner, Andrea, Battke, Florian, Hadaschik, Dirk, Schulze, Martin, Weißgraeber, Stephanie, Han, Chung-Ting, Kopp, Maria, Frick, Maximilian, Klumpp, Bernhard, Tietze, Nicola, Amaral, Teresa, Martus, Peter, Sinnberg, Tobias, Eigentler, Thomas, Keim, Ulrike, Garbe, Claus, Döcker, Dennis, Biskup, Saskia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625062/
https://www.ncbi.nlm.nih.gov/pubmed/31300034
http://dx.doi.org/10.1186/s40425-019-0659-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625062/
https://www.ncbi.nlm.nih.gov/pubmed/31300034
http://dx.doi.org/10.1186/s40425-019-0659-0

Ejemplares similares